Pfizer announces REFLECTIONS B357-02 study meets main goal
The Phase 3, multi-national, randomized, double blind, two-arm, parallel group study is designed to evaluate PF-06438179 (infliximab-Pfizer) versus Remicade in combination with methotrexate when administered intravenously to treat patients with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to methotrexate therapy.
The trial, which compared PF-06438179 to Remicade, proved that PF-06438179 showed the same efficiency as the originator product at 14 weeks. The results of the trial were measured by the American College of Rheumatology 20 (ACR20).
Pfizer is developing PF-06438179 to be a possible Remicade biosimilar.